Malaria infection, disease and mortality among children and adults on the coast of Kenya.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
17 Jun 2020
Historique:
received: 07 03 2020
accepted: 12 06 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 30 1 2021
Statut: epublish

Résumé

Malaria transmission has recently fallen in many parts of Africa, but systematic descriptions of infection and disease across all age groups are rare. Here, an epidemiological investigation of parasite prevalence, the incidence of fevers associated with infection, severe hospitalized disease and mortality among children older than 6 months and adults on the Kenyan coast is presented. A prospective fever surveillance was undertaken at 6 out-patients (OPD) health-facilities between March 2018 and February 2019. Four community-based, cross sectional surveys of fever history and infection prevalence were completed among randomly selected homestead members from the same communities. Paediatric and adult malaria at Kilifi county hospital was obtained for the 12 months period. Rapid Diagnostic Tests (CareStart™ RDT) to detect HRP2-specific to Plasmodium falciparum was used in the community and the OPD, and microscopy in the hospital. Crude and age-specific incidence rates were computed using Poisson regression. Parasite prevalence gradually increased from childhood, reaching 12% by 9 years of age then declining through adolescence into adulthood. The incidence rate of RDT positivity in the OPD followed a similar trend to that of infection prevalence in the community. The incidence of hospitalized malaria from the same community was concentrated among children aged 6 months to 4 years (i.e. 64% and 70% of all hospitalized and severe malaria during the 12 months of surveillance, respectively). Only 3.7% (12/316) of deaths were directly attributable to malaria. Malaria mortality was highest among children aged 6 months-4 years at 0.57 per 1000 person-years (95% CI 0.2, 1.2). Severe malaria and death from malaria was negligible above 15 years of age. Under conditions of low transmission intensity, immunity to disease and the fatal consequences of infection appear to continue to be acquired in childhood and faster than anti-parasitic immunity. There was no evidence of an emerging significant burden of severe malaria or malaria mortality among adults. This is contrary to current modelled approaches to disease burden estimation in Africa and has important implications for the targeting of infection prevention strategies based on chemoprevention or vector control.

Sections du résumé

BACKGROUND BACKGROUND
Malaria transmission has recently fallen in many parts of Africa, but systematic descriptions of infection and disease across all age groups are rare. Here, an epidemiological investigation of parasite prevalence, the incidence of fevers associated with infection, severe hospitalized disease and mortality among children older than 6 months and adults on the Kenyan coast is presented.
METHODS METHODS
A prospective fever surveillance was undertaken at 6 out-patients (OPD) health-facilities between March 2018 and February 2019. Four community-based, cross sectional surveys of fever history and infection prevalence were completed among randomly selected homestead members from the same communities. Paediatric and adult malaria at Kilifi county hospital was obtained for the 12 months period. Rapid Diagnostic Tests (CareStart™ RDT) to detect HRP2-specific to Plasmodium falciparum was used in the community and the OPD, and microscopy in the hospital. Crude and age-specific incidence rates were computed using Poisson regression.
RESULTS RESULTS
Parasite prevalence gradually increased from childhood, reaching 12% by 9 years of age then declining through adolescence into adulthood. The incidence rate of RDT positivity in the OPD followed a similar trend to that of infection prevalence in the community. The incidence of hospitalized malaria from the same community was concentrated among children aged 6 months to 4 years (i.e. 64% and 70% of all hospitalized and severe malaria during the 12 months of surveillance, respectively). Only 3.7% (12/316) of deaths were directly attributable to malaria. Malaria mortality was highest among children aged 6 months-4 years at 0.57 per 1000 person-years (95% CI 0.2, 1.2). Severe malaria and death from malaria was negligible above 15 years of age.
CONCLUSION CONCLUSIONS
Under conditions of low transmission intensity, immunity to disease and the fatal consequences of infection appear to continue to be acquired in childhood and faster than anti-parasitic immunity. There was no evidence of an emerging significant burden of severe malaria or malaria mortality among adults. This is contrary to current modelled approaches to disease burden estimation in Africa and has important implications for the targeting of infection prevention strategies based on chemoprevention or vector control.

Identifiants

pubmed: 32552891
doi: 10.1186/s12936-020-03286-6
pii: 10.1186/s12936-020-03286-6
pmc: PMC7301992
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

210

Subventions

Organisme : Wellcome Trust
ID : 103602
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212176
Pays : United Kingdom

Références

BMC Med. 2014 Feb 04;12:22
pubmed: 24495312
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
Trans R Soc Trop Med Hyg. 1999 Feb;93 Suppl 1:59-64
pubmed: 10450428
Am J Trop Med Hyg. 2002 Aug;67(2):137-40
pubmed: 12389936
PLoS One. 2014 Sep 02;9(9):e106197
pubmed: 25180495
Nature. 2017 Oct 26;550(7677):515-518
pubmed: 29019978
Lancet. 2012 Feb 4;379(9814):413-31
pubmed: 22305225
Adv Parasitol. 2002;52:235-64
pubmed: 12521262
Lancet. 2012 Aug 11;380(9841):559-60
pubmed: 22883497
Glob Health Action. 2012 Sep 03;5:1-8
pubmed: 22944365
Lancet Glob Health. 2014 Apr;2(4):e216-24
pubmed: 24782954
Malar J. 2009 Oct 19;8:231
pubmed: 19840372
PLoS Med. 2016 Jun 28;13(6):e1002047
pubmed: 27352303
Epidemiol Rev. 2010;32:38-55
pubmed: 20203105
Am J Trop Med Hyg. 1994 Aug;51(2):123-37
pubmed: 8074247
PLoS Med. 2018 Jan 10;15(1):e1002486
pubmed: 29320495
Proc Biol Sci. 2015 Feb 22;282(1801):20142657
pubmed: 25567652
Wellcome Open Res. 2019 Apr 8;4:67
pubmed: 31595228
Acta Trop. 1993 Jun;54(1):55-72
pubmed: 8103627
Malar J. 2014 Aug 22;13:328
pubmed: 25145498
PLoS Med. 2016 Nov 22;13(11):e1002171
pubmed: 27875530
Lancet. 2014 Sep 13;384(9947):1005-70
pubmed: 25059949
Nature. 2005 Nov 24;438(7067):492-5
pubmed: 16306991
J Med Microbiol. 2000 Dec;49(12):1053-1055
pubmed: 11129715
PLoS One. 2019 Jul 25;14(7):e0219853
pubmed: 31344062
Lancet Infect Dis. 2014 Jun;14(6):476-88
pubmed: 24813159
Malar J. 2009 Aug 06;8:190
pubmed: 19660116
Trans R Soc Trop Med Hyg. 2003 Jul-Aug;97(4):369-72
pubmed: 15259458
Nat Med. 1999 Mar;5(3):340-3
pubmed: 10086393
Glob Health Action. 2014 Oct 29;7:25369
pubmed: 25377329
Elife. 2014 Apr 24;3:e02130
pubmed: 24843017
Malar J. 2007 Sep 25;6:131
pubmed: 17894879
Glob Health Action. 2014 Oct 29;7:25593
pubmed: 25377342
Philos Trans R Soc Lond B Biol Sci. 1997 Sep 29;352(1359):1385-94
pubmed: 9355131
Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents
pubmed: 19136431
Am J Trop Med Hyg. 2005 Mar;72(3):243-8
pubmed: 15772314
Malar J. 2019 Jul 23;18(1):247
pubmed: 31337411
Lancet Infect Dis. 2003 Jun;3(6):349-58
pubmed: 12781507
Trop Med Int Health. 2014 Sep;19 Suppl 1:7-131
pubmed: 25214480
Lancet. 1992 Aug 8;340(8815):351-5
pubmed: 1353814
Malar J. 2008 Feb 26;7:36
pubmed: 18302770
BMC Med. 2019 Jul 8;17(1):124
pubmed: 31280724
Malar J. 2009 Jan 07;8:4
pubmed: 19128453
J Infect Dis. 2005 Jun 1;191(11):1932-9
pubmed: 15871128
Arch Public Health. 2018 Jul 26;76:39
pubmed: 30065835
Trop Med Int Health. 2003 Sep;8(9):793-802
pubmed: 12950665
Am J Trop Med Hyg. 1996 Jun;54(6):613-9
pubmed: 8686780
Trop Med Int Health. 2006 Apr;11(4):540-50
pubmed: 16553938
Trans R Soc Trop Med Hyg. 2000 Nov-Dec;94(6):645-51
pubmed: 11198648
BMC Med. 2014 Dec 12;12:227
pubmed: 25495076
Malar J. 2019 Nov 21;18(1):371
pubmed: 31752891
Elife. 2018 Aug 21;7:
pubmed: 30129437
PLoS One. 2010 Feb 01;5(2):e8988
pubmed: 20126547
PLoS One. 2015 Jul 24;10(7):e0134061
pubmed: 26207758
Parasitol Today. 1996 Jun;12(6):236-40
pubmed: 15275204
Malar J. 2007 Jan 17;6:3
pubmed: 17233881
N Engl J Med. 2016 Dec 22;375(25):2435-2445
pubmed: 27723434
Malar J. 2016 Dec 8;15(1):591
pubmed: 27931229

Auteurs

Alice Kamau (A)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. akamau@kemri-wellcome.org.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. akamau@kemri-wellcome.org.

Grace Mtanje (G)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Christine Mataza (C)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Ministry of Health, Kilifi County Government, Kilifi, Kenya.

Gabriel Mwambingu (G)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Neema Mturi (N)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Shebe Mohammed (S)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Gerald Ong'ayo (G)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Gideon Nyutu (G)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Amek Nyaguara (A)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Philip Bejon (P)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

Robert W Snow (RW)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH